Efficacy of SGLT2 inhibitor for nonalcoholic fatty liver disease: a randomized controlled trial

Efficacy of SGLT2 inhibitor for nonalcoholic fatty liver disease: a randomized controlled trial - Efficacy of SGLT2 inhibitor for NAFLD

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000026057

Enrollment

120

Registered

2017-03-23

Start date

2017-04-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic fatty liver disease

Interventions

SGLT2 inhibitor group normal diet group

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: NAFLD patients with type 2 diabetes

Exclusion criteria

Exclusion criteria: other chronic hepatitis patients alcoholic hepatitis patients with hepatocellular carcinoma type 1 diabetes BMI under 20

Design outcomes

Primary

Measure	Time frame
liver function and steatosis after 24 months	—

Countries

Japan

Contacts

Public Contacteiji kakazu

Tohoku university hospital Gastroenterology

kakazu@coral.ocn.ne.jp022-717-7171

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026